Dr. Daniel Spratt on Artera’s Post‑RP test:
“[It] uses clinical and pathologic features + digital pathology, running AI to help ID patients at low vs high risk of recurrence and metastasis.”
Thanks @UroTimes + Hannah Clarke for the feature.
https://t.co/81ShDfFaKT
#ArteraAI
We're heading to #SUO2026!
The Artera team looks forward to connecting with the urologic oncology community and discussing how AI-powered biomarkers can help inform personalized prostate cancer care.
#ArteraOnTheGo
Big news! The ArteraAI Prostate Test (Post-RP) is now included in the @NCCN Guidelines for Prostate Cancer as a risk stratification tool following biochemical recurrence after surgery.
Another milestone in personalized care.
https://t.co/y5JOlmUwo4
The #NCCN#prostatecancer guidelines now include the ArteraAI Prostate Test (Post-RP), an AI-based digital pathology tool, for risk stratification in biochemical recurrence after radical prostatectomy. 🔗 https://t.co/So1cG3AJtg
The Artera team is heading to the Puerto Rico Urological Association Annual Meeting to connect with colleagues and discuss advances in personalized prostate cancer care.
See you there!
#ArteraOnTheGo
In @UrologyTimes, Dr. Daniel Spratt discusses new STAR-CAP benchmarking findings and what they mean for evaluating multimodal AI.
Watch the full series: https://t.co/yQVhn2QBXF
That's a wrap on #LUGPA2026!
Thank you to everyone who connected with the Artera team in Chicago. We enjoyed the conversations and the opportunity to exchange ideas with the urology community.
The future of AI in cancer care depends on more than better algorithms.
In @TheAIJournal1, Artera explores why rigorous validation, real-world reliability, and strong clinical evidence are essential to responsible AI adoption.
Read the full article: https://t.co/gOLFXQC26Y
What could precision medicine look like in five years?
On PathPulse, Artera's Laura Chang shares her vision for expanding AI-powered biomarkers across diseases and making them more accessible worldwide.
Watch the interview: https://t.co/IXQBaE3qgQ
@LumeaDigital
The Artera team is heading to the @ChiUroSociety November 4 meeting!
We look forward to connecting with colleagues and discussing advances in prostate cancer care.
See you there!
#ArteraOnTheGo
Artera has received @Frost_Sullivan's 2026 Technology Innovation Leadership Award for AI-Powered Breast Cancer Stratification!
This #BreastCancerAwarenessMonth, we're proud to advance AI-driven insights for more personalized care.
Patient advocacy has helped shape precision medicine.
This #BreastCancerAwarenessMonth, Artera's Calvin Chao explores its impact on cancer care and why inclusivity matters as AI advances.
Read more: https://t.co/TEehukYSpS
We're heading to #LUGPA26!
The Artera team looks forward to connecting with the urology community and discussing how AI-powered biomarkers can help inform personalized prostate cancer care.
See you there! @UrologyUS
That's a wrap on #PathVisions26!
Thank you to everyone who connected with the Artera team. We enjoyed exchanging ideas and discussing the future of digital pathology and AI-powered diagnostics.
AI biomarkers should work across the diverse populations they're intended to serve. New data presented at #ASTRO2026 found similar performance of the ArteraAI prostate biomarker across racial and age subgroups studied, with no evidence of bias.
Read more: https://t.co/0gPdh0UTE4
We’re heading to the @AmerUrological Western Section Annual Meeting!
The Artera team looks forward to connecting with the urology community and discussing the role of AI-powered biomarkers in #ProstateCancer care.
Attending? Come say hello! 👋
#ArteraOnTheGo
Two more opportunities to connect with the Artera team this October!
We'll be attending the Dr. John Mordente Memorial Lecture at @nyulangone and the @gaurology Physicians Summit.
Reach out to set up a meeting.
#ArteraOnTheGo
This #BreastCancerAwarenessMonth, we’re highlighting research exploring how multimodal AI can provide insights into risk and treatment benefit in early-stage breast cancer.
▪️ ASCO 2026: https://t.co/jnHS0YqxhD
▪️ SABCS 2025: https://t.co/fPPykBpSZ6
More opportunities to connect with the Artera team this October! Find us at the @AmerUrological New England Section Meeting, @UPMC Radiation Oncology Meeting, and the NCUA Annual Meeting. #ArteraOnTheGo
How can AI help personalize #cancer treatment?
Artera CEO Andre Esteva shares his perspective on treatment selection, clinical validation, expanding access and what it takes to translate AI innovation into real-world cancer care.
Read more: https://t.co/xcZc5d4KPS
We’re heading to #PathVisions26!
Join the Artera team for conversations on integrated diagnostics, digital pathology and AI reimbursement, plus new data validating a multimodal AI biomarker in localized #ProstateCancer.
See where to find us 👇